71 related articles for article (PubMed ID: 9160397)
1. Survival and quality of life in HIV-positive patients treated with a polyantigenic immunomodulator.
Colón JI; Encarnación G; Ortiz Santini MR; Rodríguez Malavé MT; Santiago Delpín EA; Marchand AM
P R Health Sci J; 1997 Mar; 16(1):9-14. PubMed ID: 9160397
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the antitumor activity of a polyantigenic immunomodulator (PAI): II--Involvement of NK cells and adoptive immunotherapy.
Orraca ZM; Ríos-Olivares E; Carrasco-Canales JA; Aquino E; Marchand AM; Colón JI
Bol Asoc Med P R; 1989 Jul; 81(7):254-8. PubMed ID: 2775402
[TBL] [Abstract][Full Text] [Related]
3. Correlation of the suppressive activity of a biological response modifier on the proliferation of peripheral blood mononuclear cells and the reduction of HIV titer.
Vila LM; Ríos-Olivares E; Vila S; Ríos Z; Rivera E; Robles R; Reyes JC; Castillo X
Cell Mol Biol (Noisy-le-grand); 1997 Nov; 43(7):981-8. PubMed ID: 9449530
[TBL] [Abstract][Full Text] [Related]
4. Effect of highly active anti-retroviral therapy on CD3+/CD4+/CD8+ T lymphocyte counts in HIV seropositive Kashmiri patients: a follow up study.
Shah ZA; Rasool R; Siddiqi MA
Indian J Pathol Microbiol; 2007 Jul; 50(3):648-51. PubMed ID: 17883172
[TBL] [Abstract][Full Text] [Related]
5. Gender-specific differences in the natural history, clinical features, and socioeconomic status of HIV-infected patients: experience of a treatment centre in Vienna.
Armbruster C; Kriwanek S; Vorbach H
Wien Klin Wochenschr; 2000 Sep; 112(17):754-60. PubMed ID: 11042904
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the antitumor activity of a polyantigenic immunomodulator (PAI): I--Utilization of cimetidine and cyclosporine A.
Ríos-Olivares E; Orraca ZM; Carrasco-Canales JA; Alvarado L; Marchand AM; Colón JI
Bol Asoc Med P R; 1989 Jul; 81(7):246-53. PubMed ID: 2789052
[TBL] [Abstract][Full Text] [Related]
7. Zidovudine monotherapy versus zidovudine plus zalcitabine combination therapy in HIV-positive persons with CD4 cell counts 300-500 cells/mm3: a double-blind controlled trial. The M50003 Study Group Coordinating and Writing Committee.
Moyle GJ; Bouza E; Antunes F; Smith D; Harris R; Warburg M; Walker M
Antivir Ther; 1997 Dec; 2(4):229-36. PubMed ID: 11327442
[TBL] [Abstract][Full Text] [Related]
8. Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy.
Mathez D; Bagnarelli P; Gorin I; Katlama C; Pialoux G; Saimot G; Tubiana P; De Truchis P; Chauvin JP; Mills R; Rode R; Clementi M; Leibowitch J
Antivir Ther; 1997 Jul; 2(3):175-83. PubMed ID: 11322272
[TBL] [Abstract][Full Text] [Related]
9. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.
Idoko JA; Akinsete L; Abalaka AD; Keshinro LB; Dutse L; Onyenekwe B; Lhekwaba A; Njoku OS; Kehinde MO; Wambebe CO
West Afr J Med; 2002; 21(2):83-6. PubMed ID: 12403023
[TBL] [Abstract][Full Text] [Related]
10. CD4+ and CD8+ lymphocytes and clinical features of HIV seropositive Nigerians on presentation.
Onyemelukwe GC; Musa BO
Afr J Med Med Sci; 2002 Sep; 31(3):229-33. PubMed ID: 12751562
[TBL] [Abstract][Full Text] [Related]
11. An interim report on the effect of natural human interferon alpha (IFN-alpha) lozenges in patients seropositive for the human immunodeficiency virus type 1 (HIV-1).
Babiuch L; Mian M; Kamińska E; Szymańska B; Georgiades JA
Arch Immunol Ther Exp (Warsz); 1993; 41(3-4):213-9. PubMed ID: 7907465
[TBL] [Abstract][Full Text] [Related]
12. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
13. Impact of acute vivax malaria on the immune system and viral load of HIV-positive subjects.
Chen X; Xiao B; Shi W; Xu H; Gao K; Rao J; Zhang Z
Chin Med J (Engl); 2003 Dec; 116(12):1810-20. PubMed ID: 14687465
[TBL] [Abstract][Full Text] [Related]
14. [Quantification of viremia in patients infected with human immunodeficiency virus with different degrees of immunosuppression].
Soriano V; Gómez-Cano M; Mas A; Villalba N; Castilla J; Adrados M; Laguna F; Polo R; González-Lahoz J
Rev Clin Esp; 1997 Dec; 197(12):810-3. PubMed ID: 9477671
[TBL] [Abstract][Full Text] [Related]
15. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
[TBL] [Abstract][Full Text] [Related]
16. Safety and activity of zalcitabine and zidovudine combination in HIV-positive people with CD4 cell counts < or = 300 cells/mm3. The Roche M50002 Study Group.
Moyle GJ; Walker M; Harris R; Kellagher A; Warburg M
Antivir Ther; 1996 Aug; 1(3):180-8. PubMed ID: 11322252
[TBL] [Abstract][Full Text] [Related]
17. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.
Gathe JC; Wood R; Sanne I; DeJesus E; Schürmann D; Gladysz A; Garris C; Givens N; Elston R; Yeo J
Clin Ther; 2006 May; 28(5):745-54. PubMed ID: 16861096
[TBL] [Abstract][Full Text] [Related]
18. Secular trends in the survival of HIV-infected homosexual men in Amsterdam and Vancouver estimated from a death-included CD4-staged Markov model.
Hendriks JC; Craib KJ; Veugelers PJ; van Druten HA; Coutinho RA; Schechter MT; van Griensven GJ
Int J Epidemiol; 2000 Jun; 29(3):565-72. PubMed ID: 10869332
[TBL] [Abstract][Full Text] [Related]
19. Long-term methadone treatment: effect on CD4+ lymphocyte counts and HIV-1 plasma RNA level in patients with HIV infection.
Quang-Cantagrel ND; Wallace MS; Ashar N; Mathews C
Eur J Pain; 2001; 5(4):415-20. PubMed ID: 11743707
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption.
Harrer E; Bäuerle M; Ferstl B; Chaplin P; Petzold B; Mateo L; Handley A; Tzatzaris M; Vollmar J; Bergmann S; Rittmaier M; Eismann K; Müller S; Kalden JR; Spriewald B; Willbold D; Harrer T
Antivir Ther; 2005; 10(2):285-300. PubMed ID: 15865223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
